- €7.57bn
- €10.67bn
- $4.80bn
- 91
- 22
- 98
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.62 | ||
| PEG Ratio (f) | 2.25 | ||
| EPS Growth (f) | 9.55% | ||
| Dividend Yield (f) | 0.75% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.89 | ||
| Price to Tang. Book | 91.59 | ||
| Price to Free Cashflow | 30.11 | ||
| Price to Sales | 1.68 | ||
| EV to EBITDA | 11.29 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.44% | ||
| Return on Equity | 24.45% | ||
| Operating Margin | 15.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,605 | 3,566.3 | 4,014.9 | 4,348.6 | 4,801.2 | 5,260.74 | 5,708.89 | 2.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +8.34 | -42.78 | +45.01 | -13.74 | +40.37 | +8.96 | +10.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides specialized rehabilitative treatment on an inpatient basis. It operates hospitals in 37 states and Puerto Rico, with concentrations in Florida and Texas. It operates 161 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. The Company provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals also treat patients with or recovering from the COVID-19 virus. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
Directors
- Leo Higdon NEC (74)
- Mark Tarr PRE (59)
- Douglas Coltharp CFO (59)
- Barbara Jacobsmeyer CEX (55)
- Anthony Hernandez CHO
- Patrick Darby EVP (56)
- Edmund Fay SVP (54)
- Melanie Lewis SVP
- Mark Miller SVP
- Andrew Price CAO (54)
- Elissa Charbonneau OTH (61)
- Christopher Reidy DRC (64)
- Gregory Carmichael IND (59)
- John Chidsey IND (58)
- Donald Correll IND (71)
- Yvonne Curl IND (66)
- Charles Elson IND (61)
- Joan Herman IND (67)
- Leslye Katz IND (66)
- Patricia Maryland IND (67)
- John Maupin IND (74)
- Nancy Schlichting IND (67)
- L. Edward Shaw IND (76)
- Terrance Williams IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 22nd, 1984
- Public Since
- September 24th, 1986
- No. of Shareholders
- 6,438
- No. of Employees
- 22,356
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Frankfurt Stock Exchange- Shares in Issue
- 100,140,031
- Address
- 9001 Liberty Pkwy, BIRMINGHAM, 35242-7509
- Web
- https://www.encompasshealth.com/
- Phone
- +1 2059677116
- Auditors
- PricewaterhouseCoopers LLP
Latest News for HSOA
Upcoming Events for HSOA
Q1 2024 Encompass Health Corp Earnings Release
Q1 2024 Encompass Health Corp Earnings Call
Encompass Health Corp Annual Shareholders Meeting
Encompass Health Corp Annual Shareholders Meeting
Q2 2024 Encompass Health Corp Earnings Release
Similar to HSOA
Doccheck AG
Frankfurt Stock Exchange
Dr Wiesent Sozial gemeinnuetzige GmbH
Frankfurt Stock Exchange
MATERNUS-Kliniken-AG
Frankfurt Stock Exchange
MedNation AG
Frankfurt Stock Exchange
Synlab AG
Frankfurt Stock Exchange
FAQ
As of Today at 19:07 UTC, shares in Encompass Health are trading at €75.50. This share price information is delayed by 15 minutes.
Shares in Encompass Health last closed at €75.50 and the price had moved by +36.04% over the past 365 days. In terms of relative price strength the Encompass Health share price has outperformed the FTSE Global All Cap Index by +25.48% over the past year.
The overall consensus recommendation for Encompass Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Encompass Health dividend yield is 0.75% based on the trailing twelve month period.
Last year, Encompass Health paid a total dividend of $0.60, and it currently has a trailing dividend yield of 0.75%.Looking ahead, the next dividend pay date is 2024-04-15.
We do not have data on when Encompass Health is to next pay dividends. The historic dividend yield on Encompass Health shares is currently 0.75%.
To buy shares in Encompass Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €75.50, shares in Encompass Health had a market capitalisation of €7.57bn.
Here are the trading details for Encompass Health:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: HSOA
Based on an overall assessment of its quality, value and momentum Encompass Health is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Encompass Health is €82.97. That is 9.9% above the last closing price of €75.50.
Analysts covering Encompass Health currently have a consensus Earnings Per Share (EPS) forecast of $3.97 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Encompass Health. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +15.29%.
As of the last closing price of €75.50, shares in Encompass Health were trading +19.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Encompass Health PE ratio based on its reported earnings over the past 12 months is 19.62. The shares last closed at €75.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Encompass Health's management team is headed by:
- Leo Higdon - NEC
- Mark Tarr - PRE
- Douglas Coltharp - CFO
- Barbara Jacobsmeyer - CEX
- Anthony Hernandez - CHO
- Patrick Darby - EVP
- Edmund Fay - SVP
- Melanie Lewis - SVP
- Mark Miller - SVP
- Andrew Price - CAO
- Elissa Charbonneau - OTH
- Christopher Reidy - DRC
- Gregory Carmichael - IND
- John Chidsey - IND
- Donald Correll - IND
- Yvonne Curl - IND
- Charles Elson - IND
- Joan Herman - IND
- Leslye Katz - IND
- Patricia Maryland - IND
- John Maupin - IND
- Nancy Schlichting - IND
- L. Edward Shaw - IND
- Terrance Williams - IND